Skip to main content

Table 3 Cardiac catheterization data

From: Glycosylated hemoglobin (HbA1c) levels and clinical outcomes in diabetic patients following coronary artery stenting

 

Non-Diabetic (n = 2181)

Good-control DM (n = 291)

Poor-control DM (n = 412)

P-value*

P-value†

P-value‡

Type C lesion

1458 (66.9)

203 (69.8)

280 (68.0)

0.33

0.69

0.62

CTO

78 (3.6)

6 (2.1)

11 (2.7)

0.23

0.46

0.63

3-vessel disease

358 (16.8)

57 (20.2)

102 (25.1)

0.18

<0.0001

0.12

RVD < 3 mm

1092 (50.1)

165 (56.7)

236 (57.3)

0.04

0.006

0.88

SSL > 30 mm

896 (41.1)

128 (44.0)

174 (42.2)

0.35

0.66

0.70

CR

1312 (60.2)

164 (56.4)

213 (51.7)

0.21

0.001

0.22

Drug-eluting stent

1159 (54.6)

192 (67.1)

272 (66.8)

<0.0001

<0.0001

0.86

Number of stents

1.3 ± 0.6

1.3 ± 0.6

1.3 ± 0.5

0.33

0.41

0.81

  1. Data are presented as mean ± SD or n (%).
  2. * Non-diabetic patients versus good-control (diabetic patients with HbA1c ≤ 7%).
  3. † Non-diabetic patients versus poor-control (diabetic patients with HbA1c > 7%).
  4. ‡ Good-control versus poor-control diabetic patients.
  5. CR, complete revascularization CTO, chronic total occlusion; RVD, reference vessel diameter; SSL, sum of the stents’ length.
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840